Plasticell secures funding for red blood cell substitute development

By Melissa Fassbender contact

- Last updated on GMT

Plasticell is collaborating with the University of Edinburgh and Kings College London. (Image: iStock/Sashkinw)
Plasticell is collaborating with the University of Edinburgh and Kings College London. (Image: iStock/Sashkinw)

Related tags: Bone marrow

Plasticell is advancing multiple projects through which it will develop and manufacture red blood cell substitutes for human clinical transfusion and progress preclinical trials.

The cell therapy developer has secured Biomedical Catalyst funding of more than £920,000 ($1.2m) from Innovate UK.

Dr. Yen Choo, Executive Chairman of Plasticell, told us the funding will enable the discovery and development of manufacturing process for red blood cells derived from induced pluripotent stem cells (iPSC).

Plasticell will work with the University of Edinburgh (UoE) in combining of two innovative technologies: Plasticell’s CombiCult technology and lineage specific reporter cell lines that were developed by Professor Forrester's group at UoE​,” Choo said.

The use of fluorescent reporter cell lines facilitates Plasticell’s screening capability because the desired phenotype can be detected in real time in live cells during the screening process​,” he added.

The project is set to last two years, from April 2017 to March 2019, and is part of the company’s hematopoietic cell therapy portfolio.

The portfolio includes the expansion of umbilical cord- and bone- derived hematopoietic stem cells, as well as blood platelet and immune cell manufacturing for oncology applications.

As part of this work, Plasticell has also announced a partnership with Kings College London to progress preclinical trials of its artificial blood platelet product manufactured from iPSCs.

Kings College will contribute its expertise in in vivo​ models to characterize the dynamics, lifespan, safety, and efficacy of transfused platelets, according to the company.

Related news

Show more

Related products

show more

baxter_bloomington_facility_larger

Sterile Injectables Contract Manufacturing

Baxter BioPharma Solutions | 02-Apr-2018 | Product Brochure

Baxter BioPharma Solutions' award-winning facility in Bloomington, Indiana, USA, is a leader in sterile contract manufacturing of injectable products.

lyo_development

Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

How will Brexit affect the Pharmaceutical Industry?

How will Brexit affect the Pharmaceutical Industry?

Source BioScience Ltd | 08-Mar-2018 | Technical / White Paper

Have you prepared your strategy for the outcome of Brexit to ensure that you can continue to supply the UK market?
Source BioScience is a CRO with...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Related suppliers

Follow us

Products

View more